Larvol Delta - Oculis-Announces-Positive-OCS05-Phase-2-ACUITY-Trial-in-Acute-Optic-Neuritis-Met-Primary-Safety-Endpoint-and-Key-Secondary-Efcacy-Endpoints-Opening-Development-Pathways-as-a-Potential-FirstinClass-Neuroprotective-Therapy

privosegtor (OCS-05) - Oculis

https://www.globenewswire.com/news-release/2025/01/06/3004350/0/en/Oculis-Announces-Positive-OCS-05-Phase-2-ACUITY-Trial-in-Acute-Optic-Neuritis-Met-Primary-Safety-Endpoint-and-Key-Secondary-Efficacy-Endpoints-Opening-Development-Pathways-as-a-Pot.html

Jan 6, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next